UCB to sponsor trials at ‘giant site without borders’

By Flora Southey contact

- Last updated on GMT

(Image: Getty/oatawa)
(Image: Getty/oatawa)
Neurology and immunology trial participants will undertake "site-less" clinical trials under a partnership between Science 37 and drugmaker UCB.

According to the strategic collaboration, UCB-sponsored studies will use Science 37’s mobile research platform, the Network Oriented Research Assistant (NORA), to offer "site-less" trials.

The decentralized​ "Metasite" clinical trial model engages with subjects remotely to encourage greater retention of participants and reduce recruitment times.

“Science 37 is made up of one-part in-house technology team, the rest is a decentralized physician network who connect directly to patients 24/7/375 using our proprietary mobile platform,” ​explained Science 37 CEO Belinda Tan.

“We think of ourselves as a giant site without borders,” ​she added.

The partnership will also help UCB-sponsored studies reach remote or underserved communities, we were told.

The first ‘site-less’ UCB trial for Paediatric restless leg syndrome (RLS) is expected to begin this year.

Strategic collaborations

Science 37’s Metasite platform is attracting increased attention in the clinical development space. 

In December last year, Otsuka Pharmaceutical announced​ a strategic collaboration to explore the patient-centric trial method.

Additionally, in March 2018 Novartis​ – an early investor​ in Science 37 – committed​ to conducting up to ten clinical trials to scale up the "site-less" model.

Related news

Show more

Related products

show more

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

Standardizing data with NCI controlled terminology

Standardizing data with NCI controlled terminology

Formedix | 18-Jul-2022 | Technical / White Paper

The use of consistent terminology within and between studies is critical to enabling an efficient trial process. CDISC standards such as CDASH, SDTM, SEND...

Planning Your First-In-Human Trial

Planning Your First-In-Human Trial

Altasciences | 15-Jul-2022 | Technical / White Paper

A first-in-human (FIH) clinical trial is a significant milestone in the development of a potential new drug. A successfully conducted FIH trial provides...

Related suppliers

Follow us


View more